Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

The stock's fall snapped a two-day winning streak.

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business ...

Vertex Pharmaceuticals Inc. closed $57.78 short of its 52-week high ($519.88), which the company reached on November 8th.

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Novo Nordisk is a bargain stock with tremendous growth potential. Vertex Pharmaceuticals has seven clear paths to growth ...

The vanzacaftor triple offers a more convenient dosing (once daily) than Vertex's blockbuster drug Trikafta. It's also more ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% ...

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

In a report released today, Michael Yee from Jefferies upgraded Vertex Pharmaceuticals (VRTX – Research Report) to a Buy, with a price target ...